[HTML] frontiersin.org

[HTML][HTML] Comparison of pd-1 inhibitors in patients with advanced esophageal squamous cell carcinoma in the second-line setting

YX Zhou, P Chen, YT Sun, B Zhang, MZ Qiu - Frontiers in Oncology, 2021 - frontiersin.org
Background KEYNOTE-181, ATTRACTION-3, and ESCORT trials have opened the era of
programmed death 1 (PD-1) inhibitors in the second-line therapy for esophageal squamous …
被引用次数：6 相关文章
[HTML] nih.gov

[HTML][HTML] Comparison of PD-1 Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma in the Second-Line Setting

YX Zhou, P Chen, YT Sun, B Zhang… - Frontiers in Oncology, 2021 - ncbi.nlm.nih.gov
Background KEYNOTE-181, ATTRACTION-3, and ESCORT trials have opened the era of
programmed death 1 (PD-1) inhibitors in the second-line therapy for esophageal squamous …

Comparison of PD-1 Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma in the Second-Line Setting

YX Zhou, P Chen, YT Sun, B Zhang… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Background KEYNOTE-181, ATTRACTION-3, and ESCORT trials have opened the era of
programmed death 1 (PD-1) inhibitors in the second-line therapy for esophageal squamous …

Comparison of PD-1 Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma in the Second-Line Setting.

YX Zhou, P Chen, YT Sun, B Zhang, MZ Qiu - Frontiers in Oncology, 2021 - europepmc.org
Background KEYNOTE-181, ATTRACTION-3, and ESCORT trials have opened the era of
programmed death 1 (PD-1) inhibitors in the second-line therapy for esophageal squamous …